Cellectis S.A. (EPA:ALCLS)
France
· Delayed Price · Currency is EUR 1.222
+0.026 (2.17%)
Apr 1, 2025, 1:26 PM CET
Cellectis Revenue
In the year 2024, Cellectis had annual revenue of $49.22M USD with 435.37% growth. Cellectis had revenue of $15.17M in the quarter ending December 31, 2024, with 662.06% growth.
Revenue
$49.22M
Revenue Growth
+435.37%
P/S Ratio
2.28
Revenue / Employee
$221.70K
Employees
222
Market Cap
86.22M EUR
Revenue Chart
* This company reports financials in USD.
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 49.22M | 40.02M | 435.37% |
| Dec 31, 2023 | 9.19M | -16.53M | -64.26% |
| Dec 31, 2022 | 25.72M | -12.87M | -33.35% |
| Dec 31, 2021 | 38.60M | -20.97M | -35.20% |
| Dec 31, 2020 | 59.56M | 36.57M | 159.09% |
| Dec 31, 2019 | Pro | Pro | Pro |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
| Dec 31, 2015 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Sanofi | 44.29B |
| EssilorLuxottica Société anonyme | 26.51B |
| Sartorius Stedim Biotech | 2.78B |
| bioMérieux | 3.98B |
| Eurofins Scientific SE | 6.95B |
| Ipsen | 3.57B |
| Virbac | 1.40B |
| emeis Société anonyme | 5.43B |
Cellectis News
- 17 days ago - Cellectis S.A. (CLLS) Q4 2024 Earnings Call Transcript - Seeking Alpha
- 18 days ago - Why Rubrik Shares Are Trading Higher By Over 20%; Here Are 20 Stocks Moving Premarket - Benzinga
- 18 days ago - Cellectis Non-GAAP EPS of -$0.16 beats by $0.05, revenue of $33.22M beats by $23.63M - Seeking Alpha
- 18 days ago - Cellectis Reports Financial Results for the Fourth Quarter and Full Year 2024 and Provides a Business Update - GlobeNewsWire
- 24 days ago - Cellectis to Report Fourth Quarter and Full Year 2024 Financial Results on March 13, 2025 - GlobeNewsWire
- 5 weeks ago - Cellectis Presents 'Smart CAR T' Strategy to Enhance Efficacy Against Solid Tumors at AACR-IO 2025 - Benzinga
- 5 weeks ago - Cellectis Presents ‘Smart CAR T' Strategy to Enhance Efficacy Against Solid Tumors at AACR-IO 2025 - GlobeNewsWire
- 2 months ago - Cellectis S.A announces potential resale of up to 44M shares - Seeking Alpha